RO948 has good in vivo kinetic distribution and brain uptake, with low off-target binding [17]; PI2620 has a high affinity for pathological tau aggregates and has entered clinical trials [18]; results for JNJ311 are promising in trials of rodent and non-human primate tissue [19]; MK6240 binds specifically to one site on NFT-rich AD brain tissue and neither binds to off-target sites nor has an affinity for amyloid plaques [20–22]. Here, MAPT is linked to Alzheimer disease.